News for Mersana Therapeutics, Inc. (0M4.F)

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2020 Earnings Conference Call February 26, 2021, 08:00 AM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and...

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -27.27% and -97.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Steven Cohen Ups the Ante on Affimed, Stocks: AFMD,BMRN,NVAX,VRTX,INCY,REPL,MRSN, Steven Cohen, release date:Feb 09, 2021

Steven Cohen Ups the Ante on Affimed, Stocks: AFMD,BMRN,NVAX,VRTX,INCY,REPL,MRSN, Steven Cohen, release date:Feb 09, 2021

CAMBRIDGE, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Insiders were taking advantage of secondary ...

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Insiders were taking advantage of ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) ...

Today's Daily Dose brings you news about the FDA lifting the partial clinical hold on Marker Therapeutics' phase II post-transplant acute myeloid leukemia trial; Rhythm selling its Rare Pediatric Disease Priority Review Voucher for $100 million; Hoth Therapeutics' financing agreement; Millendo discontinuing further development of MLE-301 for the treatment of menopausal vasomotor symptoms.

Toward the end of trading Tuesday, the Dow traded up 0.83% to 30,474.00 while the NASDAQ rose 0.94% to 12,817.22. The S&P also rose, gaining 0.90% to ...